Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Recommendation of “Buy” from Brokerages

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Get Free Report) has earned an average recommendation of “Buy” from the nine ratings firms that are currently covering the company, MarketBeat reports. Nine investment analysts have rated the stock with a buy rating. The average 12-month price objective among brokers that have issued ratings on the stock in the […]

Leave a Reply

Your email address will not be published.

Previous post Fortune Brands Innovations, Inc. (NYSE:FBIN) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Next post Comparing LPL Financial (NASDAQ:LPLA) and JPMorgan Chase & Co. (NYSE:JPM)